We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Settles Cancer Treatment IP Skirmish With Genentech

Law360, New York (March 27, 2012, 3:02 PM EDT) -- GlaxoSmithKline has settled a suit with Genentech Inc. and nonprofit cancer treatment center City of Hope over two patents that relate to blood cancer treatment, Glaxo partner Genmab A/S said Tuesday.

The dispute concerned U.S. Patents No. 6,331,415 and 7,923,221, the "Cabilly patents," which relate to recombinant antibody production for ofatumumab, which also goes by the GSK brand name Arzerra. GSK is Dutch biotech company Genmab's development and commercial collaborator for ofatumumab, according to Genmab.

A Genentech spokeswoman, Robin Snyder, said Genentech was satisfied with the settlement agreement.

“We are pleased with the settlement reached with GSK, under which it has...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS